Please login to the form below
diabetic macular edema
This page shows the latest diabetic macular edema news and features for those working in and with pharma, biotech and healthcare.
FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
Cimerli is interchangeable for retinal indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularisation.
Latest news
-
Eylea growth closes the gap with Lucentis
Armed with new indications such as diabetic macular edema (DME), Eylea (aflibercept) can now compete with rival Lucentis (ranibizumab) sold by Roche and Novartis on a more equal footing and sales ... visual impairment due to macular oedema resulting from
-
Fresh approval for Roche's Lucentis as competition heats up
drug. Lucentis (ranibizumab) has become the first medicine in the US to be cleared to treat diabetic retinopathy in people with diabetic macular edema (DME), which affects around 750, 000 Americans ... Lucentis' approval "gives patients with diabetic
-
Bayer files Eylea for diabetes complication in EU
Looks to keep with Novartis’ Lucentis. Bayer is trying to win approval for a third indication for its big-selling eye disease treatment Eylea, namely the treatment of diabetic macular edema ... DME). Eylea (aflibercept) - also known as VEGF Trap-Eye -
-
Lucentis cleared in Europe for pathological myopia
Lucentis was originally developed by Genentech - which has US marketing rights - and is already approved for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular ... edema secondary to retinal vein
-
Novartis posts strong Q1 2011 results
The company's new product for the treatment of vision loss due to diabetic macular edema, Lucentis (ranibizumab), which was also approved for use in the EU, produced sales worth $444m.
More from news
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
in development for diabetic macular edema (DME) and uveitis.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
